super-pharm.co.il Listed by toufan Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On December 23, 2023, the Israeli pharmacy chain super-pharm.co.il appeared on a ransomware leak site operated by the group known as toufan. The listing asserts that internal files were taken in an attack. For customers, employees and partners whose information may sit inside those files, the practical stakes are straightforward: personal and operational records could be exposed, reused for fraud or further intrusion, or held over the organisation as leverage. Public detail remains limited; the number of people affected is unknown and the precise contents of the claimed haul have not been independently verified.

This article sets out only what the available record states, places the claim in context, and outlines concrete steps for anyone who may be concerned.

What happened

According to the reported summary, super-pharm.co.il was listed on the toufan ransomware leak site on or around December 23, 2023. The group claims to have stolen internal data through a ransomware attack that included exfiltration of files. No further technical details—such as the initial access method, the volume of data, encryption status of systems, or any ransom demand—have been disclosed in the public record. The number of people potentially affected is listed as unknown. The listing itself is a claim by the threat actor; independent confirmation of the breach or of the data’s authenticity has not been provided in the facts available here.

Inside toufan

Toufan is a ransomware group that follows the now-common double-extortion model used by many such actors. Operators typically gain access to a network, move laterally, exfiltrate selected files, and then encrypt systems or threaten to publish the stolen material if a ransom is not paid. Victims that refuse or fail to negotiate are often named on a dedicated leak site, sometimes accompanied by sample files or countdown timers. Public reporting on toufan has described it as one of several groups that advertise claimed breaches in this way, using the threat of public release to increase pressure. The group’s listings are assertions of success; they do not by themselves constitute proof that every claimed file set is complete, accurate or still under the group’s control. In the present case, the only statement tied directly to super-pharm.co.il is the leak-site listing and the accompanying claim of stolen internal data.

Who is super-pharm.co.il?

Super-Pharm is a major retail pharmacy chain operating primarily in Israel, with a substantial online presence under the domain super-pharm.co.il. Organisations of this type typically manage large volumes of customer records (names, contact details, loyalty-programme data, prescription and health-related information), employee and contractor data, supplier contracts, and internal operational documents. Because pharmacies sit at the intersection of retail, healthcare and personal identity, a compromise can affect both commercial operations and sensitive personal information. A listing of this nature therefore carries weight for the people who interact with the chain and for the organisation’s own continuity and regulatory obligations.

What data was at risk

The facts state only that “internal files” were claimed to have been exfiltrated in a ransomware attack. No inventory of file types, no sample data, and no confirmation of specific categories (customer lists, medical records, financial documents, credentials, etc.) have been released in the public record. Organisations in the pharmacy and retail-health sector commonly hold customer identity and contact data, purchase and loyalty histories, employee records, and various internal business files. Whether any of those categories were among the material toufan claims to possess remains unconfirmed. Readers should treat the exact contents as undisclosed.

Why it matters

For individuals, the core risk is secondary misuse of any personal information that may have been taken: targeted phishing, identity fraud, or social-engineering attempts that reference real details. For the organisation, the risks include operational disruption, regulatory scrutiny under data-protection rules, reputational damage, and the possibility that published files could aid further attacks. Because the scale and precise contents are unknown, the practical impact cannot yet be quantified; the prudent stance is to assume that any data held by the chain could theoretically be involved until clearer information emerges.

If your data was in this claimed breach

Public confirmation of individual exposure is not available, so the following steps are precautionary rather than reactive to a verified personal hit:

• Monitor bank, credit-card and loyalty-account statements for unfamiliar activity and enable transaction alerts where offered.
• Change passwords on any accounts that reuse credentials also used with Super-Pharm services, and enable multi-factor authentication.
• Treat unsolicited messages that reference Super-Pharm, prescriptions or recent purchases with caution; verify through official channels rather than links in the message.
• If you hold health-related or prescription records with the chain, ask the organisation directly (through its published support channels) whether it has issued any customer notification.
• Run a free exposure scan of your email address against known breach data sets to see whether that address has already appeared in other incidents; this will not confirm or rule out involvement in the present claim, but it can highlight existing risks.

Keep records of any suspicious contact and report confirmed fraud to the relevant authorities. Further verified details, if they become public, will clarify the true scope; until then, measured vigilance is the most useful response.

AICompiled with AI assistance from public sources and published under our editorial standards.